SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently experiencing intense market skepticism and volatility, with community members expressing frustration over stagnant price action and perceived manipulation despite strong free cash flow and share buyback programs. Many investors are actively discussing the stock as a potential buyout target or value play, while others remain critical of management's perceived lack of transparency regarding strategic growth catalysts.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors rally behind the stock's potential for oncology breakthroughs, fueled by optimism over global expansion efforts and a growing list of regulatory catalysts. While some community members remain focused on the company's long-term commercial execution and potential for a short squeeze, others are actively debating the impact of recent insider selling and the company's overall regulatory strategy.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as investors weigh a $35 cash acquisition by Hapag-Lloyd against a rival $37.50 offer from the Israeli-led Sakal Group, sparking intense debate over whether the buyout will proceed or be restructured. The community is actively discussing the stock's significant dividend potential and fundamental strength, fueled by surging freight rates and geopolitical tensions in major shipping corridors.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing increased market volatility and community debate as traders weigh its role as a core human data layer for AI against technical patterns and short-term price swings. Investors are actively discussing the stock's potential for a trend reversal, closely monitoring institutional positioning and key technical support levels to determine if it will lead in the software and AI sectors.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is drawing significant investor attention as it nears a high-stakes FDA decision for its lead kidney disease drug, with the community actively debating potential upside and strategies for navigating the upcoming PDUFA date. Discussions are heavily focused on the stock's clinical differentiation, the potential for institutional buying or a strategic buyout, and sentiment surrounding the company's competitive positioning in the IgA nephropathy market.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending as investors weigh strong box office sentiment from recent franchise releases against persistent concerns regarding linear TV valuation and corporate leadership. The community remains deeply divided, balancing optimism for an operational turnaround and streaming profitability against long-term frustration over stagnant price action and social-political discourse.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as the community debates the implications of its recent $875.8 million acquisition of DZYNE Technologies and a subsequent upgrade to its 2026 revenue guidance. While some investors remain concerned about equity dilution and share price volatility, others are highlighting the company's expanding backlog and strategic positioning within the autonomous defense sector as reasons for long-term optimism.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver Corporation is experiencing heightened volatility and intense community scrutiny as traders debate whether current price levels represent a bottoming phase or a deeper correction fueled by broader market manipulation concerns. Investors are closely monitoring technical support zones and the impact of macroeconomic variables, such as oil price fluctuations and interest rate policy expectations, on the outlook for silver miners.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending as investors focus on its pending merger with Agility Robotics, a move that positions the company as a rare pure-play exposure to the growing humanoid robotics market. Community sentiment is driven by the project's high-profile backing from major institutional players like NVIDIA and Amazon, with active discussions centering on the long-term potential for commercial scaling in industrial environments.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors bet on an imminent buyout and major trial readouts, with the community closely tracking institutional accumulation and a massive short interest dynamic. Traders are actively debating whether these factors signal a potential short squeeze or a transformative acquisition for the company's oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss

Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) has been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a s...

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near

Key PointsA major owner of Rapport Therapeutics reported selling 426,005 shares for a total value of approximately $17.18 million on April 17, 2026...

BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP)

BTIG Research restated a "buy" rating and issued a $53.00 target price on shares of Rapport Therapeutics in a research note on Wednesday...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 20,225 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the transaction, the...

Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) major shareholder Rock Ventures L.P. Third sold 426,005 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The...

Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of the company's stock in a transaction on Friday, April 17th. The stock was sold at an average price of $39.99, for a total transaction of $808,797.75. Following the completion of the...

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2% - Here's What Happened

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2% - Time to Sell...

Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading Volume - Still a Buy?

Rapport Therapeutics (NASDAQ:RAPP) Sees Strong Trading Volume - Time to Buy...

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RAPPRapport Therapeutics Inc

Fundamentals

Latest RAPP News